Three recent big-ticket M&A deals have raised expectations the global biotech sector is recovering from its two-year slump.

Meanwhile GSK is to pay $5.25 billion upfront and ... two of our core businesses and create significant new options to increase value for shareholders." The firm says it expects to return £4 ...

London open The FTSE 100 is expected to open 51 points lower on Monday, having closed down 0.73% on Friday at 8,502.35.

Then the JP Morgan 43rd Annual Healthcare Conference featured M&A news from the likes of Johnson & Johnson (JNJ) and Europe’s GSK (GSK). 3 After a business update, shares of Eli Lilly (LLY) endured ...

Karishma Gupta exemplifies strategic leadership, driving transformation and profitability in the dynamic food-tech space.

As the percentage of the global population over 65 continues to increase, the popularity of anti-aging stocks is rising in ...

Kirkland, Latham, Paul Weiss and others have replaced the likes of Sullivan & Cromwell, Clifford Chance and Slaughter and May ...

Under the terms of the agreement, GSK will pay DualityBio $30 million upfront and other pre-option milestone payments, with the total value of the ... Chines about a new treatment for acanthamoeba ...

Pharmacies play a key role in improving drug development and patient care, offering insights, clinical trial support and ...

Every year, 21.5 million people are forcibly displaced by floods, droughts, wildfires, and storms. This number ...

After two years characterized by layoffs, pipeline reorganizations, FDA delays and clinical holds, Novavax CEO John Jacobs ...

The biggest risers on the FTSE 100 were British American Tobacco, up 142p to 3,150p, ConvaTec, up 9p to 248.4p, GSK, up 45.5p ...